Trials

27 trials

• Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie DietNCT04122716 · Unknown · Phase 4 · 215 participants · Primary completion 2019-11 · BMI 32 or higher
• Effects of Liraglutide in Chronic Obstructive Pulmonary DiseaseNCT03466021 · Completed · Phase 4 · 40 participants · Primary completion 2020-05-31 · BMI 27 or higher

  population of special interest (non-obese / healthy / non-diabetic)

• Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male VolunteersNCT03835013 · Completed · NA · 26 participants · Primary completion 2021-11-01 · BMI 18 or higher

  non-weight indication: cardiovascular

• Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial DiseaseNCT04146155 · Unknown · Phase 4 · 200 participants · Primary completion 2021-12-31

  non-weight indication: cardiovascular

• Study of the Cardiometabolic Effects of Obesity PharmacotherapyNCT04575194 · Unknown · Phase 4 · 40 participants · Primary completion 2022-09-30 · BMI 27 or higher

  non-weight indication: cardiovascular

• Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee OsteoarthritisNCT05064735 · Completed · Results posted · Phase 3 · 407 participants · Primary completion 2023-07-24 · BMI 30 or higher

  non-weight indication: osteoarthritis

• Diabetes Remote Intervention to improVe Use of Evidence-based MedicationsNCT06046560 · Completed · Results posted · Phase 4 · 200 participants · Primary completion 2023-07-25

  non-weight indication: cardiovascular

• Semaglutide Use in Elderly Obese PatientsNCT05302596 · Completed · Results posted · Phase 2 · 16 participants · Primary completion 2023-10-23 · BMI 30 or higher

  non-weight indication: lean_mass, aging

• The Effect of Lixisenatide on the Effect of Pituitary HormonesNCT05804513 · Unknown · Phase 4 · 10 participants · Primary completion 2023-10-31

  non-weight indication: endocrine

• Semaglutide for Alcohol Use DisorderNCT05520775 · Completed · Results posted · Phase 2 · 48 participants · Primary completion 2024-04-12

  non-weight indication: addiction

• Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)NCT04897802 · Completed · Phase 4 · 42 participants · Primary completion 2024-04-30

  non-weight indication: endocrine

• Effects of Semaglutide in HIV-Associated LipohypertrophyNCT04019197 · Active not recruiting · Results posted · Phase 2 · 108 participants · Primary completion 2024-04-30

  non-weight indication: other_emerging

• Effects of Semaglutide on Nicotine IntakeNCT05530577 · Completed · Results posted · Phase 2 · 24 participants · Primary completion 2024-05-13

  non-weight indication: addiction

• Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolusNCT06057077 · Unknown · Phase 1, Phase 2 · 120 participants · Primary completion 2024-12-31

  population of special interest (non-obese / healthy / non-diabetic)

• Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or ObeseNCT06445075 · Completed · Phase 2 · 102 participants · Primary completion 2025-03-04
• Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal FunctionNCT06608433 · Completed · NA · 22 participants · Primary completion 2025-10-31

  non-weight indication: kidney, endocrine

• Exenatide for Smoking Cessation and Prevention of Weight GainNCT05610800 · Completed · Phase 2 · 140 participants · Primary completion 2025-11-07

  non-weight indication: addiction

• Semaglutide for Post-Smoking Cessation Weight ManagementNCT06173778 · Recruiting · Phase 2 · 197 participants · Primary completion 2026-07-01 · BMI 27 or higher

  non-weight indication: addiction

• DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot StudiesNCT07483801 · Not yet recruiting · Phase 4 · 112 participants · Primary completion 2027-04 · BMI 30 or higher

  non-weight indication: cardiovascular

• Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)NCT03884075 · Recruiting · Phase 2 · 104 participants · Primary completion 2027-09-03

  non-weight indication: liver, addiction

• The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With ObesityNCT07218445 · Recruiting · Phase 4 · 40 participants · Primary completion 2027-09-18 · BMI 27 or higher

  non-weight indication: aging

• Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or TirzepatideNCT06657209 · Recruiting · Phase 4 · 104 participants · Primary completion 2027-12-15

  population of special interest (non-obese / healthy / non-diabetic)

• Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)NCT07218354 · Recruiting · Phase 3 · 622 participants · Primary completion 2029-03-31

  non-weight indication: addiction

• Fibrosis Lessens After Metabolic SurgeryNCT06374875 · Recruiting · Phase 4 · 120 participants · Primary completion 2029-05-31 · BMI 35 or higher

  non-weight indication: liver, addiction

• GLP-1 RA for Stage 1 Type 1 DiabetesNCT07430332 · Not yet recruiting · Phase 2 · 15 participants · Primary completion 2029-06-01

  population of special interest (non-obese / healthy / non-diabetic)

• Focusing on the Menopausal Transition to Improve Mid-Life Women's HealthNCT06975111 · Recruiting · Phase 2, Phase 3 · 200 participants · Primary completion 2029-10-31

  non-weight indication: cardiovascular, aging

• Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic SyndromeNCT07770282 · Not yet recruiting · Phase 3 · 600 participants · Primary completion 2030-07-30

  non-weight indication: cardiovascular, psychiatric